Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$1,063.22 USD

1,063.22
137,405

+7.65 (0.73%)

Updated Jul 24, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.

HRMY or REGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRMY vs. REGN: Which Stock Is the Better Value Option?

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why

by Zacks Equity Research

Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe

by Zacks Equity Research

The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.

Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.

Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug

by Zacks Equity Research

Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.

Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs

by Zacks Equity Research

Roche (RHHBY) gets CHMP recommendation for a label expansion of ophthalmology drug Vabysmo (faricimab) and PiaSky (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria.

Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down

by Zacks Equity Research

Intellia (NTLA) appoints Edward Dulac as its new chief financial officer after Glenn Goddard steps down from his role with effect from Jun 30.

Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.

Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry

by Zacks Equity Research

Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.

Sheraz Mian headshot

Top Stock Reports for Procter & Gamble, ServiceNow & Lockheed Martin

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), ServiceNow, Inc. (NOW) and Lockheed Martin Corporation (LMT), as well as a micro-cap stock Steel Partners Holdings L.P. (SPLP).

Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion

by Zacks Equity Research

The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Bryan Hayes headshot

Health Care Stocks Show Relative Strength as S&P 500 Stalls

by Bryan Hayes

Several stocks are breaking out and trading near all-time highs.

FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD

by Zacks Equity Research

Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate

by Zacks Equity Research

J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.

Regeneron (REGN) Announces Positive Data on Oncology Candidate

by Zacks Equity Research

Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.

Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales

by Zacks Equity Research

Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.

Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag

by Zacks Equity Research

Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Intellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates. Stock rises.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE